查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1798010

2032 年注意力不足過動症治療市場預測：按藥物類型、治療類型、給藥途徑、分銷管道、年齡層、技術和地區進行的全球分析

Attention Deficit Hyperactivity Disorder Treatment Market Forecasts to 2032 - Global Analysis By Drug Type, Therapy Type, Route of Administration, Distribution Channel, Age Group, Technology and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球注意力不足過動症(ADHD) 治療市場預計在 2025 年達到 262.097 億美元，到 2032 年將達到 482.209 億美元，預測期內的複合年成長率為 9.1%。

注意力不足過動症(ADHD) 的治療涉及多種方法，旨在控制注意力不集中、衝動和過動等核心症狀。這些方法包括使用興奮劑和非興奮劑藥物、行為療法、認知訓練和教育介入。主要目標是提高注意力，減少衝動行為，並增強不同年齡層（包括兒童、青少年和成人）ADHD 患者的日常功能。

根據世界衛生組織（WHO）的數據，截至2022年10月18日，全球冠狀病毒（COVID-19）確診病例已超過622,389,418例。

提高認知和早期篩檢工作

大眾對過動症（ADHD）和其他神經多樣性障礙的認知正在穩步提高，從而促進了早期診斷和更積極的治療方法。教育宣傳活動和倡導工作正在幫助減少對過動症的污名化，並鼓勵家庭尋求專業協助。醫療保健系統正在採用更廣泛的篩檢通訊協定，以便在更年輕的時候發現過動症的症狀。這種轉變推動了對專業診斷工具和個人化護理計劃的需求。包括人工智慧評估在內的技術進步，使早期檢測更加準確，也更加便利。政府的支持和政策改革正在進一步加速學校和診所早期篩檢舉措的實施。

長期治療費用高昂

治療過動症通常需要持續的心理治療、藥物和行為支持，這給許多家庭帶來了經濟負擔。數年累積的治療費用可能會阻礙持續的護理，尤其是在低收入社區。過動症相關服務的保險覆蓋範圍仍然不穩定，進一步加重了經濟負擔。此外，高昂的費用限制了人們獲得先進治療方法和能夠改善治療效果的數位工具。儘管對多動症綜合解決方案的需求日益成長，但這種經濟障礙正在減緩市場成長。

非藥物治療的發展

人們對藥物相關副作用的擔憂日益加劇，促使人們對非藥物治療過動症（ADHD）的方法越來越感興趣，包括認知行為療法、神經反饋和數位療法。這些替代療法對患者和看護者頗具吸引力，因為它們副作用較少，並且可以根據個人需求進行客製化。與遠端醫療平台的整合使得這些治療可以遠距進行，從而擴大醫療資源匱乏地區的覆蓋範圍。行動應用程式和遊戲化干預措施因其引人入勝且方便用戶使用的模式而日益流行。隨著對個人化和更​​安全治療方案的需求不斷成長，非藥物療法代表著一個充滿希望的成長領域。

對誤診和過度診斷的擔憂

過動症 (ADHD) 的症狀通常與其他疾病的症狀重疊，導致準確診斷困難且容易出錯。過度依賴主觀評估可能導致誤診和不恰當的治療方案。在某些情況下，正常的行為改變會被誤認為是 ADHD，進而引發倫理和醫學的擔憂。過度診斷會增加醫療成本，並導致不必要的用藥。這些問題可能會削弱人們對診斷工具的信心，並延遲上市。

COVID-19的影響：

新冠疫情加速了過動症（ADHD）評估和治療工具向數位化的轉變。封鎖和保持社交距離的措施擾亂了傳統的面對面評估，推動了遠端醫療服務的快速普及。遠端平台使過動症患者能夠獲得持續的護理，即使在危機期間也能確保護理的連續性。疫情也凸顯了擴充性的心理健康解決方案的重要性，從而增加了對數位化治療的投資。行動應用程式和線上療法作為診所護理的便捷替代方案，越來越受到關注。

預測期內，興奮劑市場預計將成為最大的市場

興奮劑類藥物預計將在預測期內佔據最大的市場佔有率，這得益於其在症狀管理方面的有效性。這些藥物包括哌甲酯和安非他命，被廣泛使用，並得到了大量臨床研究的支持。它們能夠改善注意力、衝動控制和執行功能，使其成為過動症（ADHD）治療的基石。儘管有副作用的擔憂，興奮劑仍然是許多患者的第一線治療藥物。配方的不斷創新正在提高安全性並降低濫用的可能性。隨著認知度和診斷率的提高，對興奮劑類藥物治療的需求預計將保持強勁。

預計行動醫療應用將在預測期內實現最高的複合年成長率

預計行動醫療應用領域將在預測期內呈現最高成長率。這些應用為使用者提供了便利的治療、監控和教育資源取得途徑，尤其適合年輕使用者。遊戲化鍛鍊、提醒和進度追蹤等功能提升了使用者的參與度和依從性。與穿戴式裝置和遠端醫療平台的整合進一步增強了其實用性。隨著數位素養的提高和智慧型手機普及率的提升，行動應用正成為過動症管理的重要工具。其擴充性和個人化使其成為拓展傳統臨床環境以外醫療服務的理想選擇。

比最大的地區

由於人們對神經發育障礙的認知不斷提高以及政府的支持措施，預計亞太地區將在預測期內佔據最大的市場佔有率。人工智慧篩檢工具、行動應用程式和雲端基礎系統等技術進步正在提高診斷的準確性和治療覆蓋率。政府支持的措施、在地化內容和策略合作是塑造市場格局的關鍵發展。熱門趨勢包括遠端醫療醫療和互動治療平台。醫療保健支出的不斷成長，加上都市區的不斷擴張，正在推動全部區域對客製化且可及的多動症治療方案的需求。

複合年成長率最高的地區：

預計北美在預測期內的複合年成長率最高。這得益於其強大的醫療基礎設施、較高的診斷率以及對心理健康計畫的充足資金支持。該地區在採用人工智慧診斷和遠端醫療平台等先進技術方面處於領先地位。教育機構和職場擴大整合過動症支持工具，以促進整體性。政府撥款和私人投資正在加速研究和產品開發。隨著對個人化治療和數位化解決方案的需求不斷成長，北美仍然是一個充滿活力且快速發展的過動症治療市場。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球注意力不足過動症(ADHD) 治療市場（依藥物類型）

  • 興奮劑
    • 安非他命
    • 哌甲酯
    • Lisdexamfetamine
    • 右哌甲酯
  • 無刺激性
    • 阿托西汀
    • 胍法辛
    • 可樂定
    • 安非他酮
  • 其他藥物類型

6. 全球注意力不足過動症(ADHD) 治療市場（依治療類型）

  • 行為療法
  • 家長培訓
  • 認知行為治療（CBT）
  • 社交技能培訓
  • 飲食與營養

7. 全球注意力不足過動症(ADHD) 治療市場（依給藥途徑）

  • 口服
  • 經皮
  • 其他

8. 全球注意力不足過動症(ADHD) 治療市場（按分銷管道）

  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 專科診所

9. 全球注意力不足過動症(ADHD) 治療市場（按年齡層）

  • 孩子們
  • 青年
  • 成人

10. 全球注意力不足過動症(ADHD) 治療市場（按技術）

  • 數位治療學
  • 基於人工智慧的診斷工具
  • 遊戲化認知訓練
  • 行動醫療應用程式
  • 其他技術

11. 全球注意力不足過動症(ADHD) 治療市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章：公司概況

  • Takeda Pharmaceutical
  • Neos Therapeutics
  • Novartis AG
  • KemPharm Inc.
  • Pfizer Inc.
  • NeuroSigma Inc.
  • Eli Lilly and Company
  • Rhodes Pharmaceuticals
  • Johnson & Johnson
  • Bausch Health Companies
  • Teva Pharmaceutical
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals
  • Corium Inc.
  • Supernus Pharmaceuticals
  • Ironshore Pharmaceuticals
  • Tris Pharma
  • Akili Interactive
  • Aytu BioPharma
  • Sun Pharmaceutical
Product Code: SMRC30380

According to Stratistics MRC, the Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market is accounted for $26209.70 million in 2025 and is expected to reach $48220.90 million by 2032 growing at a CAGR of 9.1% during the forecast period. Attention Deficit Hyperactivity Disorder (ADHD) treatment involves various approaches aimed at managing the core symptoms of inattention, impulsivity, and hyperactivity. These methods may include the use of stimulant or non-stimulant medications, behavioral therapies, cognitive training, and educational interventions. The primary objective is to help individuals with ADHD improve their attention span, reduce impulsive actions, and enhance daily functioning across different age groups, including children, teens, and adults.

According to the World Health Organization's report, manifestation of coronavirus (COVID-19) has resulted in more than 622,389,418 confirmed cases infected individuals worldwide as of 18 October, 2022.

Market Dynamics:

Driver:

Growing awareness and early screening initiatives

Public awareness of ADHD and other neurodiverse conditions is steadily increasing, leading to earlier diagnoses and more proactive treatment approaches. Educational campaigns and advocacy efforts have helped reduce stigma and encourage families to seek professional help. Healthcare systems are adopting broader screening protocols to identify ADHD symptoms at younger ages. This shift is driving demand for specialized diagnostic tools and personalized care plans. Technological advancements, including AI-powered assessments, are making early detection more accurate and accessible. Government support and policy reforms are further accelerating the adoption of early screening initiatives across schools and clinics.

Restraint:

High cost of long-term treatment

Managing ADHD often requires ongoing therapy, medication, and behavioral support, which can be financially burdensome for many families. The cumulative cost of treatment over several years can deter consistent care, especially in low-income regions. Insurance coverage for ADHD-related services remains inconsistent, adding to the financial strain. High costs also limit access to advanced therapies and digital tools that could improve outcomes. This economic barrier slows market growth despite rising demand for comprehensive ADHD solutions.

Opportunity:

Development of non-pharmacological treatments

Amid growing concerns over medication side effects, interest is rising in non-drug approaches to managing ADHD, such as cognitive behavioral therapy, neurofeedback, and digital therapeutics. These alternatives offer fewer side effects and can be tailored to individual needs, making them attractive to patients and caregivers. Integration with telehealth platforms allows remote delivery of these treatments, expanding access in underserved areas. Mobile apps and gamified interventions are gaining popularity for their engaging and user-friendly formats. As demand for personalized and safer options rises, non-pharmacological treatments present a promising growth area.

Threat:

Misdiagnosis or overdiagnosis concerns

ADHD symptoms often overlap with other conditions, making accurate diagnosis challenging and prone to error. Overreliance on subjective assessments can lead to misdiagnosis, resulting in inappropriate treatment plans. In some cases, normal behavioral variations are mistakenly labeled as ADHD, raising ethical and medical concerns. Overdiagnosis can inflate healthcare costs and contribute to unnecessary medication use. These issues undermine trust in diagnostic tools and may slow market adoption.

Covid-19 Impact:

The COVID-19 pandemic accelerated the shift toward digital ADHD assessment and treatment tools. Lockdowns and social distancing measures disrupted traditional in-person evaluations, prompting rapid adoption of telehealth services. Remote platforms enabled continued care for individuals with ADHD, ensuring treatment continuity during the crisis. The pandemic also highlighted the importance of scalable mental health solutions, leading to increased investment in digital therapeutics. Mobile apps and online therapy gained traction as accessible alternatives to clinic-based care.

The stimulants segment is expected to be the largest during the forecast period

The stimulants segment is expected to account for the largest market share during the forecast period, due to their proven efficacy in symptom management. These drugs, including methylphenidate and amphetamines, are widely prescribed and supported by extensive clinical research. Their ability to improve focus, impulse control, and executive functioning makes them a cornerstone of ADHD therapy. Despite concerns about side effects, stimulants remain the first-line treatment for many patients. Ongoing innovation in drug formulations is enhancing safety and reducing misuse potential. As awareness and diagnosis rates rise, the demand for stimulant-based therapies is projected to remain strong.

The mobile health applications segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the mobile health applications segment is predicted to witness the highest growth rate. These apps offer convenient access to therapy, monitoring, and educational resources, especially for younger users. Features like gamified exercises, reminders, and progress tracking enhance user engagement and adherence. Integration with wearable devices and telehealth platforms further boosts their utility. As digital literacy improves and smartphone penetration increases, mobile apps are becoming a vital tool in ADHD management. Their scalability and personalization make them ideal for expanding care beyond traditional clinical settings.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, owing to rising awareness of neurodevelopmental disorders and supportive government initiatives. Technological advancements such as AI-powered screening tools, mobile applications, and cloud-based systems are improving diagnostic accuracy and treatment reach. Government-backed initiatives, localized content, and strategic collaborations are key developments shaping the landscape. Popular trends include telehealth-enabled care and interactive therapeutic platforms. Rising healthcare spending, coupled with urban expansion, is boosting demand for tailored and accessible ADHD treatment options throughout the region.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to strong healthcare infrastructure, high diagnosis rates, and robust funding for mental health programs. The region is a leader in adopting advanced technologies like AI-driven diagnostics and telehealth platforms. Educational institutions and workplaces are increasingly integrating ADHD support tools to promote inclusivity. Government grants and private investments are accelerating research and product development. With rising demand for personalized care and digital solutions, North America remains a dynamic and rapidly evolving market for ADHD treatment.

Key players in the market

Some of the key players in Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market include Takeda Pharmaceutical, Neos Therapeutics, Novartis AG, KemPharm Inc., Pfizer Inc., NeuroSigma Inc., Eli Lilly and Company, Rhodes Pharmaceuticals, Johnson & Johnson, Bausch Health Companies, Teva Pharmaceutical, Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals, Corium Inc., Supernus Pharmaceuticals, Ironshore Pharmaceuticals, Tris Pharma, Akili Interactive, Aytu BioPharma, and Sun Pharmaceutical.

Key Developments:

In July 2025, Pfizer Inc. announced the completion of a global, ex-China, licensing agreement with 3SBio, Inc. granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio's SSGJ-707, a bispecific antibody targeting PD-1 and VEGF developed using 3SBio's proprietary CLF2 platform. This agreement solidifies Pfizer at the forefront of innovative cancer research and further enhances the company's robust oncology pipeline.

In June 2025, Novartis announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. ("Regulus"). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the "Shares"), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis.

In September 2024, Takeda committed JPY4.6 billion to five new Global Corporate Social Responsibility (CSR) partners as part of the company's ongoing commitment to improving health systems resiliency in low and middle-income countries around the world. This commitment demonstrates Takeda's focus on tackling systemic disparities and supporting local leadership in strengthening health infrastructure, empowering health workforce.

Drug Types Covered:

  • Stimulants
  • Non-Stimulants
  • Other Drug Types

Therapy Types Covered:

  • Behavioral Therapy
  • Parent Training
  • Cognitive Behavioral Therapy (CBT)
  • Social Skills Training
  • Diet and Nutrition

Routes of Administration Covered:

  • Oral
  • Transdermal
  • Others

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Clinics

Age Groups Covered:

  • Children
  • Adolescents
  • Adults

Technologies Covered:

  • Digital Therapeutics
  • AI-Based Diagnostic Tools
  • Gamified Cognitive Training
  • Mobile Health Applications
  • Other Technologies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Stimulants
    • 5.2.1 Amphetamines
    • 5.2.2 Methylphenidate
    • 5.2.3 Lisdexamfetamine
    • 5.2.4 Dexmethylphenidate
  • 5.3 Non-Stimulants
    • 5.3.1 Atomoxetine
    • 5.3.2 Guanfacine
    • 5.3.3 Clonidine
    • 5.3.4 Bupropion
  • 5.4 Other Drug Types

6 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Therapy Type

  • 6.1 Introduction
  • 6.2 Behavioral Therapy
  • 6.3 Parent Training
  • 6.4 Cognitive Behavioral Therapy (CBT)
  • 6.5 Social Skills Training
  • 6.6 Diet and Nutrition

7 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Transdermal
  • 7.4 Others

8 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Specialty Clinics

9 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Age Group

  • 9.1 Introduction
  • 9.2 Children
  • 9.3 Adolescents
  • 9.4 Adults

10 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Technology

  • 10.1 Introduction
  • 10.2 Digital Therapeutics
  • 10.3 AI-Based Diagnostic Tools
  • 10.4 Gamified Cognitive Training
  • 10.5 Mobile Health Applications
  • 10.6 Other Technologies

11 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Takeda Pharmaceutical
  • 13.2 Neos Therapeutics
  • 13.3 Novartis AG
  • 13.4 KemPharm Inc.
  • 13.5 Pfizer Inc.
  • 13.6 NeuroSigma Inc.
  • 13.7 Eli Lilly and Company
  • 13.8 Rhodes Pharmaceuticals
  • 13.9 Johnson & Johnson
  • 13.10 Bausch Health Companies
  • 13.11 Teva Pharmaceutical
  • 13.12 Mallinckrodt Pharmaceuticals
  • 13.13 Amneal Pharmaceuticals
  • 13.14 Corium Inc.
  • 13.15 Supernus Pharmaceuticals
  • 13.16 Ironshore Pharmaceuticals
  • 13.17 Tris Pharma
  • 13.18 Akili Interactive
  • 13.19 Aytu BioPharma
  • 13.20 Sun Pharmaceutical

List of Tables

  • Table 1 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Drug Type (2024-2032) ($MN)
  • Table 3 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Stimulants (2024-2032) ($MN)
  • Table 4 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Amphetamines (2024-2032) ($MN)
  • Table 5 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Methylphenidate (2024-2032) ($MN)
  • Table 6 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Lisdexamfetamine (2024-2032) ($MN)
  • Table 7 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Dexmethylphenidate (2024-2032) ($MN)
  • Table 8 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Non-Stimulants (2024-2032) ($MN)
  • Table 9 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Atomoxetine (2024-2032) ($MN)
  • Table 10 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Guanfacine (2024-2032) ($MN)
  • Table 11 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Clonidine (2024-2032) ($MN)
  • Table 12 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Bupropion (2024-2032) ($MN)
  • Table 13 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Other Drug Types (2024-2032) ($MN)
  • Table 14 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 15 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Behavioral Therapy (2024-2032) ($MN)
  • Table 16 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Parent Training (2024-2032) ($MN)
  • Table 17 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Cognitive Behavioral Therapy (CBT) (2024-2032) ($MN)
  • Table 18 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Social Skills Training (2024-2032) ($MN)
  • Table 19 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Diet and Nutrition (2024-2032) ($MN)
  • Table 20 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 21 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 22 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 23 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Others (2024-2032) ($MN)
  • Table 24 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 25 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 26 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 27 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 28 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 29 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Age Group (2024-2032) ($MN)
  • Table 30 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Children (2024-2032) ($MN)
  • Table 31 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Adolescents (2024-2032) ($MN)
  • Table 32 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Adults (2024-2032) ($MN)
  • Table 33 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Technology (2024-2032) ($MN)
  • Table 34 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
  • Table 35 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By AI-Based Diagnostic Tools (2024-2032) ($MN)
  • Table 36 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Gamified Cognitive Training (2024-2032) ($MN)
  • Table 37 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Mobile Health Applications (2024-2032) ($MN)
  • Table 38 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Other Technologies (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.